前列腺癌
Search documents
美媒:拜登自开始接受前列腺癌放射治疗后首次公开露面
Huan Qiu Wang· 2025-10-19 04:16
Core Points - Former President Biden publicly appeared for the first time after starting radiation therapy for prostate cancer on October 18 [1] - Biden was diagnosed with prostate cancer in May, with cancer cells having spread to his bones, and his Gleason score is 9, indicating a high level of aggressiveness [3] - Biden underwent surgery in September to remove skin cancer from his forehead, and he is currently receiving radiation and hormone therapy for his aggressive prostate cancer [3]
拜登接受癌症放射治疗
Xin Hua Wang· 2025-10-12 07:37
拜登2024年竞选连任时,与共和党对手特朗普的电视辩论表现不佳,引发外界对其健康状态的担忧。拜登随后退出竞选,今年1月正式卸任总统职 务。 美国癌症学会数据显示,前列腺癌是导致美国男性患癌死亡的"第二大杀手",仅次于肺癌。(林芮竹) 这是2024年5月13日在美国华盛顿白宫拍摄的时任美国总统拜登。新华社发(亚伦摄) 拜登办公室5月宣布,82岁的拜登被确诊患有前列腺癌,且癌细胞已扩散至骨骼。此前发布的消息称,拜登出现泌尿系统症状。根据医疗界广泛采 用的评估前列腺癌恶性程度和侵袭性的分级标准"格利森评分",癌症侵袭性评分从6分到10分不等,8分至10分为高度侵袭性,而拜登病情诊断达9 分。另外,拜登于9月接受手术,切除了额头部位的皮肤癌病灶。 新华社北京10月12日电 美国前总统约瑟夫·拜登的发言人11日说,拜登正在接受针对其所患侵袭性前列腺癌的放射和激素治疗。 ...
拜登被拍到头上有明显切口痕迹 发言人:接受皮肤癌手术
Xin Jing Bao· 2025-09-05 05:04
9月4日,拜登被拍到头部出现伤口,其发言人回应称他近期接受了皮肤癌手术。美媒发布拜登8月出行 的视频,他离开一教堂时头上有明显切口痕迹。报道称拜登接受手术以切除皮肤癌细胞,并称他手术恢 复良好。拜登在2023年任内曾切除胸部的癌性皮肤病变,当时被诊断为基底细胞癌。2025年5月,82岁 的拜登被诊断患有侵袭性前列腺癌,癌症已扩散至骨头。 ...
拜登确诊癌症后首次露面
证券时报· 2025-05-25 03:48
美国前总统拜登近日被诊断患有侵袭性前列腺癌。 据美国全国广播公司(NBC)报道,拜登23日和夫人吉尔·拜登等一起在康涅狄格州参加了他的孙子罗伯 特·亨特·拜登二世的高中毕业典礼。 NBC称,这是拜登18日宣布被诊断出患有前列腺癌以来首次公开露面。 报道称,该活动在康涅狄格州索尔兹伯里学校举办,美国前第一夫人吉尔·拜登及拜登的女儿艾什莉·拜登 通过社交媒体发布了多张现场照片。在吉尔·拜登发布的照片中,她配文写道:"骄傲的爷爷奶奶!祝贺亨 特——我们为你感到骄傲。 " 艾什莉·拜登23日晚发布的照片显示,拜登疑似现身某机场,但具体地点尚 未明确。 来源:环球网 转载与合作可联系证券时报小助理,微信ID:SecuritiesTimes END 点击关键字可查看 潜望系列深度报道丨 股事会专栏 丨 投资小红书 丨 e公司调查 丨 时报会客厅 丨 十大明星私募访谈 丨 重大交易达成?特朗普新表态,相关公司股价飙升! 丨 特朗普,重大宣布! 丨 重磅!李家超发 声! 丨 证监会批复同意!三大行,集体宣布! 丨 罗素美国指数,启动年度重组! 丨 "爱股票 APP""侃哥说财经"等账号,关闭! 丨 买卖股票时机"恰到好处", ...
拜登前顾问:他任内就患癌了
Guan Cha Zhe Wang· 2025-05-20 09:40
Core Points - Former President Biden is reported to have been diagnosed with aggressive prostate cancer that has metastasized to the bones, raising concerns about his health during his presidency [3][5] - Ezekiel Emanuel, a former COVID-19 advisor to Biden, stated that Biden likely had cancer for several years, possibly since the beginning of his presidency [1][4] - Biden's cancer has a Gleason score of 9, indicating a high level of malignancy, and is classified as stage four, meaning it has spread [3][5] Group 1 - Biden's cancer diagnosis was made public after he reported urinary symptoms, leading to the discovery of a small nodule on his prostate [3] - The statement from Biden's office indicated that while the cancer is aggressive, it is hormone-sensitive and can be effectively managed [3] - Emanuel expressed concerns about the lack of regular health checks for sitting presidents, highlighting the importance of transparency in health matters [1][4] Group 2 - Experts have noted that once prostate cancer spreads to the bones, it is generally considered incurable, although some patients may survive for several years [5] - Former President Trump publicly expressed his support for Biden, wishing him a successful recovery, while also criticizing Biden's cognitive abilities [5][6] - Biden has faced multiple health challenges throughout his life, including two brain aneurysms in 1988 and the loss of his son to an aggressive brain cancer in 2015 [5]
拜登患癌并已扩散至骨骼,特朗普发文慰问
Huan Qiu Shi Bao· 2025-05-19 23:07
Core Points - President Biden has been diagnosed with aggressive prostate cancer that has metastasized to the bones, with a Gleason score of 9, indicating advanced stage cancer [1][2] - Despite the diagnosis, Biden's office states that his body appears to be hormone-sensitive to cancer treatment, suggesting potential for effective management [2] - Biden's health has been a topic of concern, with previous health issues including skin cancer and ongoing scrutiny regarding his cognitive abilities [3][4] Group 1 - Prostate cancer is a leading cause of cancer-related deaths among men in the U.S., with an estimated 1 in 8 men diagnosed [3] - In 2021, over 230,000 new cases of prostate cancer were reported in the U.S., with projections of over 310,000 new cases by 2025 [3] - The American Cancer Society estimates that there are currently 3.3 million men living with a prostate cancer diagnosis in the U.S. [3] Group 2 - Biden's health has been under scrutiny, especially after a poor performance in a televised debate, leading to questions about his fitness for office [4] - Internal discussions within Biden's team have reportedly included concerns about his physical decline and potential use of a wheelchair in a second term [4] - A survey indicated that 72% of voters believe Biden is not fit for office, reflecting a significant increase in public concern regarding his health [4]
该病发病率逐年上涨 重离子治疗或为患者带来治疗新希望
Mei Ri Shang Bao· 2025-05-19 22:18
Core Insights - The announcement of former President Biden's prostate cancer diagnosis has heightened public awareness of prostate cancer and its implications for health management [1][2] - Prostate cancer incidence is rapidly increasing in China, particularly among older populations, with significant implications for healthcare strategies and treatment options [2][3] Group 1: Prostate Cancer Trends - Prostate cancer has become the most common malignant tumor among men in Europe and the U.S., with a notable increase in cases in China [2] - In Zhejiang Province, the ranking of prostate cancer among male cancers has risen from fourth to third place in 2023 [2] - The incidence of prostate cancer is highly correlated with age, particularly in men over 70, and is influenced by genetic factors and lifestyle choices [2] Group 2: Early Detection and Diagnosis - Early-stage prostate cancer often presents no obvious symptoms, making PSA screening crucial for early detection [2] - The early diagnosis rate for prostate cancer in China was previously below 30%, but has improved significantly with increased PSA screening, reducing late-stage diagnosis rates from over 50% to around 30% [2] Group 3: Treatment Innovations - Heavy ion therapy offers a new treatment option for localized prostate cancer, providing precise targeting of tumors with minimal damage to surrounding tissues [3] - The five-year survival rate for low-risk patients treated with heavy ion therapy exceeds 90%, and for high-risk patients, tumor control rates improve by 15%-20% compared to photon therapy [3] - Nuclear medicine treatments are being researched to target bone metastases effectively, utilizing radioactive isotopes to minimize damage to normal tissues [4] Group 4: Future Directions - The integration of advanced technologies such as gene testing and AI imaging is expected to enhance screening and treatment efficacy for prostate cancer [4] - The establishment of comprehensive treatment centers for heavy ion therapy and accelerated nuclear drug development in Zhejiang Province is anticipated to significantly improve the five-year survival rates for prostate cancer patients [4] - A shift from passive treatment to proactive health management for men is essential for effective prostate cancer control and treatment [4]
拜登前列腺癌的启示录
和讯· 2025-05-19 10:25
Group 1 - The global incidence of prostate cancer is projected to rise from 1.4 million new cases in 2020 to 2.9 million by 2040, with deaths increasing from 375,000 to nearly 700,000 in the same period [2] - In the United States, approximately 2.0419 million new cancer cases are expected in 2025, with prostate cancer accounting for 30% of male cases, an increase of 1 percentage point from 2024 [2] - In China, new prostate cancer cases among men reached 134,200 in 2022, ranking sixth among male malignancies, with its proportion rising from 3.5% in 2016 to 5.3% in 2022, indicating a significant growth rate [3] Group 2 - The treatment options for prostate cancer primarily include drug therapy, surgical treatment, and radiation therapy, indicating a diverse market for related pharmaceutical companies [3] - Companies such as Aoxiang Pharmaceutical, which produces prostaglandin products, reported a revenue of 22.08 million yuan in 2024, a year-on-year decline of 16.56%, with a gross margin of 76.21% despite an 8.75 percentage point decrease from 2023 [3][4] - The Hong Kong-listed company, Yuan Da Pharmaceutical, has developed a targeted PSMA diagnostic drug, TLX591-CDx, which achieved nearly $517 million in sales in 2024 and has completed Phase III clinical trials in China [4]
拜登确诊患前列腺癌,“格里森评分9” 意味着什么?
第一财经· 2025-05-19 05:16
2025.05. 19 本文字数:1282,阅读时长大约2分钟 作者 | 第一财经 孙卓 美国前总统拜登办公室周日(5月18日)发表声明说,拜登被诊断出患有恶性前列腺癌,而且癌细胞 已经扩散到骨骼。 诊断书显示,拜登在格里森评分(Gleason score)中被评为9分,格林森评分是评估前列腺癌症恶 性程度的病例分级系统,最严重为10分。 "虽然这是一种更具侵袭性的疾病,但是这种癌细胞似乎对激素的治疗敏感,这使得疾病能够得到有 效管理。"拜登办公室的声明说。 几天前,拜登的一位发言人表示,前总统最近因在前列腺上发现一个"小结节"而接受了检查。 声明还说,82岁的拜登和家人正在与他的医生一起探讨治疗方案。 "道格(哈里斯丈夫)和我得知拜登总统被诊断出前列腺癌,感到难过。在此期间,我们将他和 美国国立卫生研究院(NIH)称,前列腺癌是一种发生在前列腺组织中的癌症,是美国男性最常见的癌 症,也是第二大癌症死亡原因。 匹兹堡大学医学中心泌尿肿瘤学教授戴维斯(Benjamin Davies)博士表示,根据前列腺癌细胞在 显微镜下的影像,可以将其划分为不同的等级,称为格里森评分,而格里森评分为9"意味着它是最 具侵袭性的 ...
拜登罹患恶性前列腺癌,专家说:可治
Di Yi Cai Jing· 2025-05-19 04:18
Group 1 - Prostate cancer is the second most common tumor type among men globally, with approximately 1 in 9 men diagnosed in their lifetime [1][2] - President Biden has been diagnosed with malignant prostate cancer, with cancer cells having spread to his bones, and his Gleason score is reported to be 9, indicating a highly aggressive form of the disease [1][2] - The treatment options for prostate cancer are diverse and should be personalized based on individual patient circumstances, potentially involving a combination of therapies such as hormone therapy, chemotherapy, or radiation [3] Group 2 - Recent advancements in the development of new prostate cancer drugs have been made, with the FDA approving enzalutamide (brand name: Xtandi) for a new indication in November 2023, marking it as the first approved treatment for high-risk non-metastatic castration-sensitive prostate cancer [3] - The five-year survival rate for metastatic prostate cancer in China is reported to be less than 50%, with 20%-30% of patients already having metastasis at the time of initial diagnosis [2] - Prostate cancer typically has a slower progression compared to other malignancies, allowing patients to maintain a relatively normal life and quality of life even in high-risk cases [3]